HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS).

AbstractBACKGROUND:
Although statin therapy is beneficial for preventing first strokes, the benefit for recurrent stroke and its sub-types remains unknown in Asian populations. The aim of this study is to examine the role of pravastatin in the secondary prevention of stroke in Japanese patients.
METHODS:
This is a multicenter, randomized, open-label, parallel group study of patients with noncardioembolic ischemic stroke (atherothrombotic infarction, lacunar infarction, and infarction of undetermined etiology). All patients were diagnosed with hyperlipidemia and with a total cholesterol level between 180 and 240 mg/dl at enrollment. Patients in the treatment group receive 10 mg/day of pravastatin, and those in the control group receive no statin treatment. The primary end-point is the recurrence of stroke, including transient ischemic attack. The secondary end-points include the onset of respective stroke sub-types and functional outcomes related to stroke. The patients were enrolled for five-years and will be followed up for five-years.
RESULTS:
A total of 1578 eligible patients (age: 66·2 years, men: 68·8%), including 64·2% with lacunar infarction, 25·4% with atherothrombotic infarction, and 10·4% with infarction of undetermined etiology were included in this study. Lipid levels were generally well controlled (total cholesterol: 210·0 mg/dl, low density lipoprotein cholesterol: 129·5 mg/dl) at baseline. In addition, the disability of patients was relatively mild, and cognitive function was preserved in the majority of patients.
CONCLUSION:
This article reports the rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke. Follow-ups of patients are in progress and will end in 2014.
AuthorsYoji Nagai, Tatsuo Kohriyama, Hideki Origasa, Kazuo Minematsu, Chiaki Yokota, Shinichiro Uchiyama, Setsuro Ibayashi, Yasuo Terayama, Makoto Takagi, Kazuo Kitagawa, Eiichi Nomura, Naohisa Hosomi, Toshiho Ohtsuki, Takemori Yamawaki, Yoshihiro Matsubara, Masakazu Nakamura, Yoshimitsu Yamasaki, Etsuro Mori, Masanori Fukushima, Shotai Kobayashi, Yukito Shinohara, Takenori Yamaguchi, Masayasu Matsumoto, J-STARS Investigators
JournalInternational journal of stroke : official journal of the International Stroke Society (Int J Stroke) Vol. 9 Issue 2 Pg. 232-9 (Feb 2014) ISSN: 1747-4949 [Electronic] United States
PMID24015915 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2013 The Authors. International Journal of Stroke published by World Stroke Organization.
Chemical References
  • Anticholesteremic Agents
  • Enzyme Inhibitors
  • Pravastatin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anticholesteremic Agents (therapeutic use)
  • Enzyme Inhibitors (therapeutic use)
  • Female
  • Humans
  • Japan (epidemiology)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Outpatients
  • Pravastatin (therapeutic use)
  • Secondary Prevention
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Stroke (prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: